NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Geely Automobile Holdings Limited (“Geely” or the “Company”) (OTCMKTS: GELYF; GELYY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Geely and certain of its officers and/or directors […]

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of MarineMax, Inc. (“MarineMax” or the “Company”) (NYSE: HZO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether MarineMax and certain of its officers and/or directors have engaged in

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Barnes & Noble Education, Inc. (“Barnes & Noble” or the “Company”) (NYSE: BNED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Barnes & Noble and certain of

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Duolingo, Inc. (“Duolingo” or the “Company”) (NASDAQ: DUOL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Duolingo and certain of its officers and/or directors have engaged in

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Quanex Building Products Corporation (“Quanex” or the “Company”) (NYSE: NX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Quanex and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / September 10, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=166483&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Exelixis and certain of its officers and/or directors have engaged in

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Molina and certain of its officers and/or directors have engaged

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ: ANIK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Anika and certain of its officers and/or directors have engaged